Home › Research › Disease mechanisms
Growth associated protein 43 (GAP-43) predicts brain amyloidosis in Alzheimer’s dementia continuum: an [18 F] AV-45 study
Reza Nemati, Ahmadreza Sohrabi-Ashlaghi, Parsa Saberian, Mohammad Sadeghi, Sajjad Mardani, Alireza Abadi, Ali Yaghoobpoor, Atefeh Sadat Heydari et al.. BMC Neurology, 2025-04-01
Topic: Brain proteins, microglia and lab models
Our findings revealed significantly elevated CSF GAP-43 levels in individuals with AD compared to CN and MCI groups. Furthermore, GAP-43 levels showed a significant positive correlation with tau pathology. Notably, we observed a significant association between GAP-43 and [¹⁸F] Florbetapir PET SUVR in the MCI group, suggesting that GAP-43 may serve as a reliable biomarker in the early stages of AD. This study provides evidence supporting the role of GAP-43 as a potential biomarker for AD, particularly in relation to predicting the amyloid pathology pattern in the brain in the MCI stage.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nemati, R., Sohrabi-Ashlaghi, A., Saberian, P., Sadeghi, M., Mardani, S., Abadi, A., et al. (2025). Growth associated protein 43 (GAP-43) predicts brain amyloidosis in Alzheimer’s dementia continuum: an [18 F] AV-45 study. BMC Neurology. https://doi.org/10.1186/s12883-025-04140-5
Vancouver
Nemati R, Sohrabi-Ashlaghi A, Saberian P, Sadeghi M, Mardani S, Abadi A, et al. Growth associated protein 43 (GAP-43) predicts brain amyloidosis in Alzheimer’s dementia continuum: an [18 F] AV-45 study. BMC Neurology. 2025. doi:10.1186/s12883-025-04140-5. PMID: 40170060.
BibTeX
@article{nemati2025-40170060,
author = {Nemati, Reza and Sohrabi-Ashlaghi, Ahmadreza and Saberian, Parsa and Sadeghi, Mohammad and Mardani, Sajjad and Abadi, Alireza and Yaghoobpoor, Ali and Heydari, Atefeh Sadat and others},
title = {{Growth associated protein 43 (GAP-43) predicts brain amyloidosis in Alzheimer’s dementia continuum: an [18 F] AV-45 study}},
journal = {BMC Neurology},
year = {2025},
doi = {10.1186/s12883-025-04140-5},
pmid = {40170060},
url = {https://doi.org/10.1186/s12883-025-04140-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Our findings revealed significantly elevated CSF GAP-43 levels in individuals with AD compared to CN and MCI groups.
- Furthermore, GAP-43 levels showed a significant positive correlation with tau pathology.
- Notably, we observed a significant association between GAP-43 and [¹⁸F] Florbetapir PET SUVR in the MCI group, suggesting that GAP-43 may serve as a reliable biomarker in the early stages of AD.
- This study provides evidence supporting the role of GAP-43 as a potential biomarker for AD, particularly in relation to predicting the amyloid pathology pattern in the brain in the MCI stage.
Why it matters
People with Alzheimer's disease had higher levels of GAP-43 in cerebrospinal fluid, and in the mild cognitive impairment group GAP-43 was linked to amyloid PET signal and tau pathology. This suggests GAP-43 could serve as a biomarker for early Alzheimer's disease, but the study does not test or provide any treatment.
Study details
- Participants1,639
- Evidence strengthModerate
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (BMC Neurology) |
| Journal's citation record | 1 / 4 | BMC Neurology: journal h-index 122 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,639 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Hamide Nasiri: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Tehran University of Medical Sciences: institution h-index 810 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40170060) |
| Free to read | 2 / 2 | Free to read |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Disease mechanisms
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.